CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Purple Biotech Ltd   (PPBT)
Other Ticker:  
 

Purple Biotech Ltd 's Leverage Ratio

PPBT's quarterly Leverage Ratio and Total Liabilities, Equity growth




PPBT Leverage Ratio (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity Change -27.66 % -27.66 % -27.66 % -27.66 % -18.36 %
Y / Y Total Liabilities Change 38.61 % 38.61 % 38.61 % 38.61 % 25.7 %
Leverage Ratio MRQ 0.15 0.15 0.15 0.15 0.08
Overall Ranking # 151 # 439 # 0 # 0 # 293
Seq. Equity Change 0 % 0 % 0 % -27.66 % 0 %
Seq. Total Liabilities Change 0 % 0 % 0 % 38.61 % 0 %

New: More PPBT's historic Leverage Ratio results >>


Comment on PPBT Leverage Ratio in the forth quarter 2022
Due to repayements of liabilities of 0% Purple Biotech Ltd improved Leverage Ratio in forth quarter 2022 to 0.15, above the Purple Biotech Ltd 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 42 other companies have achieved lower Leverage Ratio than Purple Biotech Ltd in the IV Quarter 2022. While Leverage Ratio total ranking has improved so far in the forth quarter 2022 to 151, from total ranking in the third quarter 2022 at 439.

Explain Leverage Ratio?
Who are PPBT Customers?
What are PPBT´s Total Liabilities?
Leverage Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 71
Overall Market # 151


Leverage Ratio Statistics
High Average Low
0.36 0.13 0.04
(Dec 31 2019)   (Dec 31 2018)




Financial Statements
Purple Biotech Ltd 's Equity $ 47 Millions Visit PPBT's Balance sheet
Purple Biotech Ltd 's Total Liabilities $ 7 Millions Visit PPBT's Balance sheet
Source of PPBT's Sales Visit PPBT's Sales by Geography


Cumulative Purple Biotech Ltd 's Leverage Ratio

PPBT's Leverage Ratio for the trailling 12 Months

PPBT Leverage Ratio

 (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity TTM Growth -27.66 % -27.66 % -27.66 % -27.66 % -18.36 %
Y / Y Total Liabilities TTM Growth 38.61 % 38.61 % 38.61 % 38.61 % 25.7 %
Leverage Ratio TTM 0.15 0.13 0.11 0.09 0.08
Total Ranking TTM # 380 # 4 # 0 # 0 # 218
Seq. Equity TTM Growth 0 % 0 % 0 % -27.66 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 0 % 38.61 % 0 %

Leverage ratio ranking by company, industry and sector >> Back to PPBT Financial Strength Comparisons >> Compare PPBT Leverage Ratio to its Peers

TTM Leverage Ratio Comment
On the trailing twelve months basis Despite of the repayements of liabilities of 0% in the trailling twelve months ending in IV Quarter 2022, Leverage Ratio improved to 0.15, below Purple Biotech Ltd 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 123, during the past 12 months, other companies have achieved lower Leverage Ratio than Purple Biotech Ltd . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2022, compared to the prior period, from 4 to 380.

Explain Leverage Ratio?
Who are PPBT Customers?
What are PPBT´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 124
Healthcare Sector # 199
Within the Market # 380


TTM Leverage Ratio Statistics
High Average Low
0.38 0.2 0.05
(Jun 30 2019)   (Dec 31 2020)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2022 MRQ Total LiabilitiesDec 31 2022 MRQ Equity
Oncolytics Biotech Inc   0.41 $ 8.297  Millions$ 20.301  Millions
Sinovac Biotech Ltd  0.41 $ 5,193.147  Millions$ 12,712.661  Millions
Calithera Biosciences Inc   0.41 $ 8.284  Millions$ 20.392  Millions
Moonlake Immunotherapeutics  0.40 $ 27.816  Millions$ 68.767  Millions
Neubase Therapeutics inc   0.40 $ 7.359  Millions$ 18.224  Millions
Amphastar Pharmaceuticals Inc   0.40 $ 213.329  Millions$ 528.658  Millions
Regulus Therapeutics Inc   0.40 $ 13.425  Millions$ 33.291  Millions
Onconova Therapeutics inc   0.40 $ 11.289  Millions$ 28.309  Millions
Integrated Biopharma Inc  0.40 $ 7.400  Millions$ 18.652  Millions
Liminal Biosciences Inc   0.39 $ 10.916  Millions$ 27.735  Millions
Liquidia Corporation  0.39 $ 35.273  Millions$ 90.422  Millions
Hookipa Pharma inc   0.39 $ 39.963  Millions$ 102.517  Millions
Cue Biopharma Inc   0.39 $ 25.601  Millions$ 65.683  Millions
I mab  0.39 $ 163.997  Millions$ 421.896  Millions
Opko Health Inc   0.39 $ 605.611  Millions$ 1,561.648  Millions
Biomarin Pharmaceutical Inc  0.38 $ 1,771.918  Millions$ 4,603.156  Millions
Magenta Therapeutics Inc   0.38 $ 40.687  Millions$ 105.958  Millions
Prophase Labs Inc   0.38 $ 24.017  Millions$ 63.631  Millions
Enveric Biosciences Inc   0.38 $ 5.517  Millions$ 14.672  Millions
Nurix Therapeutics Inc   0.37 $ 113.063  Millions$ 303.696  Millions
Marker Therapeutics inc   0.37 $ 7.205  Millions$ 19.601  Millions
23andme Holding Co   0.36 $ 273.662  Millions$ 750.992  Millions
Renovorx Inc   0.36 $ 2.204  Millions$ 6.163  Millions
Cellectar Biosciences Inc   0.35 $ 5.478  Millions$ 15.508  Millions
Tiziana Life Sciences Ltd  0.35 $ 6.906  Millions$ 19.571  Millions
Zevra Therapeutics Inc   0.35 $ 29.722  Millions$ 85.807  Millions
Longeveron Inc   0.34 $ 6.910  Millions$ 20.503  Millions
Evotec Se  0.34 $ 447.028  Millions$ 1,329.646  Millions
Neximmune Inc   0.33 $ 10.759  Millions$ 32.300  Millions
Generation Bio Co   0.33 $ 93.771  Millions$ 282.493  Millions

Date modified: 2023-03-23T13:12:32+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071